SCHEMBL13314352

SCHEMBL13314352

NCC1CC(n2cc(-c3ccc4cn[nH]c4c3)c3c(N)ncnc32)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 12/20 0.53
ABL1 P00519 7/20 0.53
IGF1R P08069 5/20 0.53
KDR P35968 4/20 0.53
JAK2 O60674 2/20 0.53
INSR P06213 2/20 0.53
LCK P06239 2/20 0.53
RET P07949 2/20 0.53
KIT P10721 2/20 0.53
PDGFRA P16234 2/20 0.53
FGFR4 P22455 2/20 0.53
FGFR3 P22607 2/20 0.53
ALK Q9UM73 2/20 0.53
NTRK1 P04629 1/20 0.53
NPM1 P06748 1/20 0.53
CSF1R P07333 1/20 0.53
LYN P07948 1/20 0.53
MET P08581 1/20 0.53
PDGFRB P09619 1/20 0.53
BCR P11274 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13314351 0.83 SRC (0.53) SRCABL1IGF1RKDRJAK2
SCHEMBL13314355 0.82 SRC (0.54) SRCABL1IGF1RKDRJAK2
SCHEMBL13314316 0.82 SRC (0.54) SRCABL1IGF1RKDRJAK2
SCHEMBL13314318 0.81 ABL1 (0.61) SRCABL1IGF1RKDRJAK2
SCHEMBL13314412 0.80 IGF1R (0.56) SRCABL1IGF1RKDRJAK2
SCHEMBL13314358 0.80 IGF1R (0.52) SRCABL1IGF1RKDRJAK2
SCHEMBL13314368 0.79 SRC (0.56) SRCABL1IGF1RKDRJAK2
SCHEMBL13314339 0.79 IGF1R (0.68) SRCABL1IGF1RKDRJAK2
SCHEMBL13314404 0.79 IGF1R (0.57) SRCABL1IGF1RKDRJAK2
SCHEMBL13314317 0.78 EGFR (0.74) SRCABL1IGF1RKDRJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160356-A1 NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2010-06-24 US disclosed
US-20100160356-A1 NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160356-A1 NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K2 SRC 266/4885ABL1 180/4885IGF1R 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.